Artelo Biosciences (ARTL) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system.

• Pipeline includes ART27.13 (dual cannabinoid agonist for cancer-related anorexia), ART26.12 (FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (proprietary CBD cocrystal for multiple potential indications).

• Product candidates are developed in accordance with regulated drug development standards, with plans for prescription-based commercialization post-approval.

• Holds multiple patents and licenses, including exclusive rights to ART27.13 and a library of FABP5 inhibitors.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $600,000; pro forma as-adjusted cash post-offering estimated at $11.4 million.

• Accumulated deficit of $63.0 million and stockholders' equity of $(1.3) million actual, $9.5 million as adjusted for the offering.

• Net tangible book value per share as of December 31, 2025, was $(4.92); post-offering, pro forma as-adjusted net tangible book value is $4.12 per share, resulting in immediate dilution of $4.07 per share to new investors.

Use of proceeds and capital allocation

• Estimated net proceeds of $10.8 million (assuming all securities sold at $7.31 per share), to be used for working capital and general corporate purposes.

• Management has broad discretion over the use of proceeds.